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ABSTRACT
Objective: Prolonged usage of neuroleptics in psychotic disorders such as schizophrenia provokes extrapyramidal symptoms that are also seen in 
Parkinson’s disease. An attempt has been made to study the neuroprotective role of Achyranthes aspera hydroalcoholic (HA) extract on haloperidol-
induced Parkinson’s symptoms in Wistar rats.
Methods: The present study deals with the antiparkinson effect of HA extract of A. aspera on haloperidol (2 mg/kg intraperitoneal administration)-
induced catatonia in Wistar rats. The motor coordination in case of haloperidol-treated animals was studied by performing rotarod test and hang test. 
Dopamine and 3,4-dihydroxyphenylacetic acid were estimated using an electrochemical detector and high-performance liquid chromatography. The 
antioxidant status was also assessed to know the neurotoxicity of haloperidol by estimating the levels of lipid peroxidation, superoxide dismutase, 
glutathione (GSH) peroxidase, and reduced GSH by performing individual assays.
Results: All these assessments were done on 24 Wistar rats which were divided into four groups (n=6). HA was administered at 200 and 400 mg/kg 
doses, 30 minutes before haloperidol treatment for 20 days. HA significantly (*p<0.05, **p<0.01) improved the antioxidant status.
Conclusion: The results shown that HA shows a protective role in haloperidol catalepsy and also possess antioxidant property.
Keywords: Achyranthes aspera, Haloperidol, Catatonia behavior, Parkinson’s disease, Levodopa.
INTRODUCTION
Parkinson’s disease (PD) is primarily characterized by degradation 
of dopamine-carrying neurons in the substantia nigra with the 
extrapyramidal symptoms such as tremors, bradykinesia, rigidness, 
and inability to maintain the normal posture [1]. The neuronal death in 
PD is due to the damage to free radicals, Lewy’s bodies formation [2]. 
In general, a combination therapy of synthetic drugs is more effective 
in Parkinson’s treatment. Levodopa is the first-line drug of PD and still 
long-term use of levodopa has many side effects [3]. Prolonged usage of 
the antipsychotic drugs such as haloperidol causes dopamine receptor 
blockade in the corpus striatum, thus producing the extrapyramidal 
effects similar to that in PD. Catalepsy produced by neuroleptic agents 
such as haloperidol is a widely accepted animal model for screening 
drugs for parkinsonism [4]. Catalepsy is the loss or decrease of the 
ability of an animal to regain its externally imposed posture. Gamma-
aminobutyric acid deficiency and cholinergic dysfunction are proved to 
be cause for catalepsy [5].
Achyranthes aspera possesses diuretic, laxative, antiasthmatic, 
hepatoprotective, nephroprotective, bronchoprotective, and antiallergic 
properties [6]. The methanolic extract of this whole plant has been 
confirmed for its anti-inflammatory, antioxidant, and antidepressant 
activities [7,8] previously and now its hydroalcoholic (HA) used to find 
its role in enhancing the dopaminergic transmission and antioxidant 
capacity in PD.
METHODS
Preparation of plant extract
The whole plant of A. aspera was obtained from Tirunelveli 
district in Tamil Nadu, and authentication (voucher specimen 
number - PARC/2015/3194) was done by Prof. Jayaraman P, Ph.D, Plant 
Anatomy Research Centre, Tambaram, Chennai-45. The plants were 
cleaned, air dried, and powdered to fine in an automix blender and are 
deep frozen. The A. aspera powder is extracted using HA in a Soxhlet 
extractor and evaporated to a concentrate by rotary evaporator at 40°C 
and preserved in a cool, dry place until its use [9].
Animals
Twenty four Wistar albino rats of 200-250 g weight were procured from 
King’s Institute, Guindy. In accordance to the IAEC guidelines, the rats 
were placed in standard laboratory conditions with room temperature 
of 25±1°C and 60% humidity. A standard balanced diet with water is 
provided to the test animals. The project proposal was approved by 
Institutional Animal Ethical Committee (IAEC 163/2015).
Drug treatment and experimental design
Twenty four animals were grouped into four, having six in each group 
(n=6). Group I received haloperidol (1.0 mg/kg, i.p), Group II received 
haloperidol (1.0 mg/kg, i.p) + L-DOPA + carbidopa (100+25 mg/kg, 
p.o) suspended in 1% tween 20, and Groups III and IV received 200 
and 400 mg/kg HA (p.o), respectively, 30 minutes before haloperidol 
injection for 20 days.
After the treatment for 20 days, all four groups of animals underwent 
the behavioral assessment tests. Then, cervical decapitation was 
performed to isolate the striatum of the brains of the animals, and 
homogenate was prepared using ice-cold phosphate-buffered saline 
solution and stored.
Catalepsy behavioral study
Haloperidol (1.0 mg/kg i.p.) used in the catalepsy induction and 
the rats were assessed for every 30 minutes up to 120 minutes by 
performing a standard bar test. Haloperidol among the antipsychotics 
produces a moderate cataleptic effect. Catalepsy was given in scores for 
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the imposed position of the front limbs placed on a 3 and 9 cm high 
wooden bar of 1 cm wide. When the both front paws were taken from 
the bar or if the animal moves its head, this can be termed as the end 
point. Levodopa (100 mg/kg) was taken as the standard drug, and the 
A. aspera HA extract was administered to three different groups (n=6 
in each group) at a dose of 200 and 400 mg/kg p.o., respectively, 1 hr 
before to the dosing of haloperidol.
If the animal is unable to regain its posture for about 10 seconds, it 
was considered to be cataleptic. Stage I – Rat is able to move freely on 
the table it is placed, score = 0. Stage II – Rat moves when touched or 
pushed, score = 0.5. Stage III – If the rat is unable to correct its posture 
in 10 s when its front paws are set alternately on a 3 cm high block, the 
score = 0.5 for each paw with a total 1 score. Stage IV – Rat could not 
remove its front paws when placed on a 9 cm high block, score = 1 with 
a total score = 2 for this stage [10].
Rotarod test
The rotarod apparatus is a rotating rod of 70 cm length and 3 cm 
diameter at the height of 50 cm above the floor and has four divisions 
where four animals can be placed each time during the study. Before 
the assessment, all the rats underwent five trials by maintaining rate 
of rotation at 30 rpm. The control rat remains on the rod for about 
5 minutes. The treated rats were kept on the rotating rod at regular 
intervals, and the time of the fall-off time was noted. The cutoff time for 
the test was 5 minutes [11].
Hang test
The neuromuscular strength of the animals was determined by the hang 
test. The rat was lifted by its tail and left on a horizontal grid mounted 20 cm 
above the hard surface and given support until it grabs on the grid with its 
fore and hind paws. The grid was then inverted for the rat to hang upside 
down [12]. The rats are to be stayed on the grid for about 30 seconds to 
1 minute. The maximum hanging time was recorded as mentioned below:
Maximum hanging timePercentage of hanging time 100
30 seconds
= ×
Assessment of dopamine and 3,4-dihydroxyphenylacetic acid 
(DOPAC) levels
The dissected brain samples were weighed, frozen at 80°C until 
assay, and homogenized in one milliliter ice-cooled 0.1 mmol/L 
perchloric acid solution containing 0.2 µg/ml L-isoproterenol hydrogen 
and 0.1 mmol/L ethylenediaminetetraacetic acid (EDTA). Tissue 
homogenates were centrifuged at 15,000 ×g at 4°C for 30 minutes, 
and the supernatant was filtered and stored at −80°C until assay. High-
performance liquid chromatography with an electrochemical detector 
and 25 cm × 0.5 cm I.D column used in the assessment of dopamine and 
DOPAC levels. The sample peak obtained is compared with the standard 
peak and expressed in microgram per gram of tissue weight [13].
Estimation of lipid peroxidation (LPO) in brain homogenate
Estimation of malondialdehyde
Three hundred microns of 10% trichloroacetic acid (TCA) were added 
to 150 µL of each sample and centrifuged at 1000 rpm for 10 minutes 
at 4°C. About 300 µL of the supernatant was incubated with 300 µL 
0.67% thiobarbituric acid at 100°C for 25 minutes. The mixture was 
cooled for 5 minutes and the thiobarbituric acid reactive substances 
(TBARS) concentration as pink stains was read in a spectrophotometer 
at 535 nm [14].
Assay of superoxide dismutase (SOD)
SOD was assessed by the inhibition of formation of nicotinamide adenine 
dinucleotide (NADH) - phenazine methosulphate nitroblue tetrazolium 
formazon complex. NADH was assessed after 90 s of incubation and the 
reaction was terminated by the addition of glacial acetic acid. The color 
formed as the end point of the reaction was extracted into the butanol 
layer and measured at 520 nm [15].
Assay of catalase (CAT)
The tissue was homogenized in isotonic buffer (pH - 7.4) and 
centrifuged at 1000 ×g for 10 minutes. 20 µl of 100-fold diluted tissue 
supernatant added to 980 µl of the assay mixture; the assay mixture 
consists of 900 µl of 10 mmol/L of H2O2, 50 µl of Tris-HCl buffer (pH - 8), 
and 30 µl of water. The degree of decomposition of H2O2 was monitored 
spectrophotometrically at 240 nm [16].
Estimation of glutathione peroxidase (GPx)
A volume of 0.1 ml of the diluted tissue was incubated at 37°C with 
reaction mixture consisting of 0.2 ml of each EDTA, sodium azide, and 
H2O2. 0.5 ml of TCA was added to this mixture to stop the reaction and 
then centrifuged at 2000 rpm. 4 ml of disodium hydrogen phosphate 
and 0.5 ml 5,5’-dithiobis nitro benzoic acid (DTNB) were added to 
0.5 ml of supernatant, and the color formation was recorded at 420 nm 
in a spectrophotometer [17].
Activity was expressed as μ moles of glutathione oxidized/minutes/mg 
protein.
Assay of reduced glutathione (GSH)
To 2 ml of the tissue homogenate and KCl mixture, add 4 ml of cold 
distilled water and 1 ml of 50% TCA. The contents were centrifuged 
at 3000 rpm for 15 minutes, and from this 2 ml of the supernatant was 
collected and 4 ml of 0.4 M Tris buffer (pH 8.9) and 0.1 ml of 0.01 M 
DTNB were added, the absorbance was read 412 nm against the blank 
reagent. For blank readings, 2 ml of distilled water was used in the place 
of tissue homogenate.
Total GSH was calculated using the formula:
Co=(A*D)/E
Where, A is absorbance at 412 nm, D is dilution factor, and E is the molar 
extinction coefficient (C=13,000 M−1 CM−1); Co is the concentration of 
GSH [17].
Statistical analysis
One-way analysis of variance followed by Dunnett’s test was 
employed for the analysis of data in catalepsy test, biochemical and 
other behavioral parameters. *p<0.01 and **p<0.05 were considered 
statistically significant.
RESULTS
An increase in the degree of catalepsy was noticed in the haloperidol 
group after 60 and 90 minutes of administration. The score was 
significantly reduced after 60 minutes with the test drug HA at 200 
and 400 mg/kg doses (Fig. 1). During the period of observation till 
120 minutes, there has been a significant reduction. The 400 mg/kg 
treated group exhibited maximum reduction in the catalepsy.
Fig. 2 shows the results of rotarod test. The retention time was reduced 
in the haloperidol-tested animals and was significantly improved in 
HA-treated groups. Among these two groups, maximum increase in the 
retention time was noted in 400 mg/kg group.
Fig. 3 shows the results of hang test. The fall-off time was reduced in 
the haloperidol group and it was improved significantly by treatment 
with the extract.
Table 1 shows the dopamine, DOPAC, and homovanillic acid levels 
which were decreased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri
dine-treated group and were significantly (*p<0.05, 0.01) increased 
on hydroalcoholic extract of A. aspera (HA) treatment, especially at 
200 mg/kg dose.
Striatal TBARS and antioxidant status are presented in Table 2. The 
striatal TBARS was significantly increased in haloperidol-treated 
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group of mice when compared to control group. HA reduced the TBARS 
level. SOD, CAT, GPx, and GSH activities were significantly decreased 
in haloperidol-treated group when compared to control group and 
were again restored significantly on treatment with HA at 200 and 
400 mg/kg doses.
DISCUSSION
Free radical damage to the central nervous system (CNS) is due to its 
high oxygen utility, increased lipid content and inadequate antioxidant 
enzymes than compared to other tissue. The free radical generation in 
the brain influences gene expression, subsequently leading to apoptosis 
and neuronal death. In the brain, an array of cellular defense systems, 
i.e., enzymatic and non-enzymatic antioxidants exists to counterbalance 
the generation of reactive oxygen species [2].
Studies show that prolonged treatment with antiparkinson drugs 
such as dopamine agonist, dopamine replenishment therapy, and 
monoamine oxidase inhibitors leads to severe side effects and 
decrease in the sensitivity for the therapy [18]. Further, typical 
neuroleptic drugs such as chlorpromazine, haloperidol, and 
reserpine use in schizophrenia lead to decrease in dopamine content 
and state of catalepsy. The cataleptic induction model by neuroleptics 
in rodents is the widely accepted model to test the extrapyramidal 
side effects of antipsychotic agents. Evidences indicate that drugs 
which produce or reduce the catalepsy in rodents might also show 
the same effects in human beings. The conversion of levodopa to 
dopamine in serotonin neurons was proved as a compensatory 
measure in PD [19,20].
Previous studies have shown that dopamine receptors in the striatum 
are involved in the neuroleptic-induced catalepsy [5]. It has been 
demonstrated that the cataleptic effects of haloperidol are mediated by 
dopamine receptors of the striatal neurons. It was also reported that the 
administration of haloperidol provokes an oxidative stress in the brain 
tissue. An increase in SOD concentration in the present work supports 
the concept. Under normal conditions, decrease in the activities of SOD, 
GPx, and CAT enzymes in the brain leads to the accumulation of oxidative 
free radicals resulting in degenerative effects [6]. At normal conditions, 
increased concentration of these enzymes would represent the rise in 
antioxidant activity and exhibits a protective mechanism in neuronal 
tissue, thus constituting the first line of defense against oxidative stress 
in our body. Hence, any decrease in the degree of catalepsy and rise in 
the SOD activity in the drug-treated groups indicates the ability of the 
drug extract to protect against the oxidative stress in the brain tissue 
and reduce the severity of haloperidol-induced catalepsy. Treatment 
with A. aspera extract increased the activity of these enzymes by 
quenching the free radicals.
Fig. 3: Effect of hydroalcoholic extract of Achyranthes aspera (HA) 
on Hang test
Fig. 2: Effect of hydroalcoholic extract of Achyranthes aspera (HA) 
on Rota rod test
Fig. 1: Effect of hydroalcoholic extract of Achyranthes aspera (HA) 
on Catalepsy behavior in mice
Table 2: Effect of hydroalcoholic extract of Achyranthes aspera (HA) on Anti-oxidant enzymes
Groups 
(n=6)















I Haloperidol (1 mg/kg) 0.93±0.84 2.56±0.04 0.12±0.01 3.28±0.13 0.09±0.04
II Haloperidol+L-DOPA+carbidopa1+100+25 1.96±0.12**a 4.39±0.07**a 0.16±0.04**a 7.79±0.09**a 0.22±0.06**a
III HA (200 mg/kg)+haloperidol 200+01 2.38±0.31*b 3.86±0.01*b 0.20±0.04*b 9.72±0.12*b 0.39+0.01*a
IV HA (400 mg/kg)+haloperidol 400+01 3.88±0.26*b 2.92±0.04**b 0.37±0.02**b 10.13+0.23**b 0.60+0.04**b
aCompared with Group-I, bCompared with Group-II, *p<0.05, **p<0.01. HA: Hydroalcoholic, SOD: Superoxide dismutase, LPO: Lipid peroxidation, CAT: Catalase, 
GPx: Glutathione peroxidase, GSH: Glutathione
Table 1: Effect of hydroalcoholic extract of Achyranthes aspera (HA) on Dopamine and DOPAC levels
Groups (n=6) Dose (mg/kg) Dopamine (mg/g of brain tissue) DOPAC
I Haloperidol (1 mg/kg) 1.56±0.04 0.73±0.02
II Haloperidol+L-DOPA+carbidopa 1+100+25 3.72±0.01**a 1.26±0.15**a
III HA (200 mg/kg)+haloperidol 200+01 4.38±0.14*b 1.68±0.04*b
IV HA (400 mg/kg)+haloperidol 400+01 6.90±0.18**b 1.94±0.01*b
aCompared with Group-I, bCompared with Group-II, *p<0.05, **p<0.01. DOPAC: 3,4-dihydroxyphenylacetic acid, HA: Hydroalcoholic
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Researches have shown that A. aspera possesses potent antioxidant 
activity that scavenges free radicals generated after the induction of 
catalepsy. Lower levels of LPO in the brains of the drug-treated groups 
and increased activities of enzymatic and non-enzymatic antioxidants 
suggest that the extract reduces oxidative stress. The methanolic extract 
of A. aspera showed no signs of lethality up to 2000 mg/kg. Hence, 
initially, two doses, i.e., 200 and 400 mg/kg of hydroalcoholic extract 
of A. aspera were selected to study their effect on haloperidol-induced 
parkinsonism in Wistar albino model. At a dose of 400 mg/kg, the HA 
extract showed a significant reduction (*p≤0.01) of the parkinsonism 
effect in Wistar albino rats.
CONCLUSION
During oxidative stress, numerous morphological and functional 
alterations are observed in the pathogenesis of many CNS disorders. 
Treatment of such neuronal disorders with A. aspera whole plant 
extract significantly decreased LPO and increases the antioxidants in 
the brain significantly. The findings of this study suggest the possible 
antioxidant role of A. aspera extract in overcoming the neurochemical 
and behavioral changes during oxidative stress. Since the catalepsy test 
has predictive value regarding extrapyramidal effects, the possibility 
of pharmacological interactions between haloperidol and A. aspera 
whole plant extract because of its effectiveness in PD can be further 
extrapolated to clinical studies for better therapy in humans.
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